References
- Cao X, Gibbs ST, Fang L, et al. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675–86
- Esguerra LEO, Beno DWA, Deriy L, et al. (2000). The effect of surgical stress on the endotoxin-induced interferon-gamma response. Shock 14:561–4
- Fisher MB, Labissiere G. (2007). The role of the intestine in drug metabolism and pharmacokinetics. Curr Drug Metab 8:694–9
- Floren LC, Bekersky I, Benet LZ, et al. (1997). Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–9
- Fromm MF, Busse D, Kroemer HK, Eichelbaum M. (1996). Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796–801
- Gibbs JP, Emery MG, McCaffery I, et al. (2011). Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol 51:830--41
- Greene RJ, Davis JA, Subramanian R, et al. (2012). Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers. Drug Metab Dispos 40:928–42
- Kolars JC, Awni WM, Merion RM, Watkins PB. (1991). First-pass metabolism of cyclosporin by the gut. Lancet 338:1488–90
- Li A, Yuan CC, Chow D, et al. (2011). Synthesis and evaluation of the metabolites of AMG 221, a clinical candidate for the treatment of type 2 diabetes. ACS Med Chem Lett 2:824–7
- Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–58
- Lown KS, Bailey DG, Fontana RJ, et al. (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545–53
- Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. (2003). Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425–61
- Paine MF, Shen DD, Kunze KL, et al. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14–24
- Quinney SK, Galinsky RE, Jiyamapa-Serna VA, et al. (2008). Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos 36:1097–101
- Rashid TJ, Martin U, Clarke H, et al. (1995). Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 40:51–8
- Strelevitz TJ, Foti RS, Fisher MB. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334–41
- Thummel KE, O'Shea D, Paine MF, et al. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491–502
- Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. (1999). Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461–71
- Uhing MR, Beno DW, Jiyamapa-Serna VA, et al. (2004). The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos 32:1325–30
- Uhing MR, Kimura RE. (1995). The effect of surgical bowel manipulation and anesthesia on intestinal glucose absorption in rats. J Clin Invest 95:2790–8
- van de Kerkhof EG, de Graaf IA, Groothuis GM. (2007). In vitro methods to study intestinal drug metabolism. Curr Drug Metab 8:658–75
- Veniant MM, Hale C, Hungate RW, et al. (2010). Discovery of a potent, orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221). J Med Chem 53:4481--7
- Yang J, Jamei M, Yeo KR, et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676–84
- Zhu X, Slatter JG, Emery MG, et al. (2012). Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate. Xenobiotica 2012 Dec 17 [Epub ahead of print]